280 related articles for article (PubMed ID: 15625915)
41. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.
Hussain S; Plückthun A; Allen TM; Zangemeister-Wittke U
Mol Cancer Ther; 2006 Dec; 5(12):3170-80. PubMed ID: 17172421
[TBL] [Abstract][Full Text] [Related]
42. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL.
Rashmi R; Kumar S; Karunagaran D
Carcinogenesis; 2005 Apr; 26(4):713-23. PubMed ID: 15661804
[TBL] [Abstract][Full Text] [Related]
43. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
44. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Cho YS; Cho-Chung YS
Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
[TBL] [Abstract][Full Text] [Related]
45. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
[TBL] [Abstract][Full Text] [Related]
46. [Apoptotic effect of bcl-XL antisense oligodeoxynucleotide mediated by lipofectin on cell strain CNE-2Z].
He GR; Zhou KY; Cai KR; Liang T; He CW; Zhang YF
Ai Zheng; 2003 Jan; 22(1):11-5. PubMed ID: 12561428
[TBL] [Abstract][Full Text] [Related]
47. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
Klasa RJ; Gillum AM; Klem RE; Frankel SR
Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
[TBL] [Abstract][Full Text] [Related]
48. Antisense activity of 2',4'-BNA targeted to bcl-xL gene in HepG2 cell.
Roongjang S; Takahashi K; Park M; Obika S; Imanishi T
Nucleic Acids Symp Ser (Oxf); 2006; (50):289-90. PubMed ID: 17150931
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
Cao XX; Mohuiddin I; Ece F; McConkey DJ; Smythe WR
Am J Respir Cell Mol Biol; 2001 Nov; 25(5):562-8. PubMed ID: 11713097
[TBL] [Abstract][Full Text] [Related]
50. Cytotoxicity of etoposide in cancer cell lines in vitro after BCL-2 and C-RAF gene silencing with antisense oligonucleotides.
Sypniewski D; Bednarek I; Gałka S; Loch T; Błaszczyk D; Sołtysik D
Acta Pol Pharm; 2013; 70(1):87-97. PubMed ID: 23610963
[TBL] [Abstract][Full Text] [Related]
51. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides.
Ackermann EJ; Taylor JK; Narayana R; Bennett CF
J Biol Chem; 1999 Apr; 274(16):11245-52. PubMed ID: 10196212
[TBL] [Abstract][Full Text] [Related]
52. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
[TBL] [Abstract][Full Text] [Related]
53. No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2013; 27(2):251-6. PubMed ID: 23422486
[TBL] [Abstract][Full Text] [Related]
54. Liposomal delivery of antisense oligonucleotides for efficient downregulation of Bcl-2 and induction of apoptosis.
Buck AC; Shen C; Schirrmeister H; Schmid-Kotsas A; Munzert G; Guhlmann A; Mehrke G; Klug N; Gross HJ; Bachem M; Reske SN
Cancer Biother Radiopharm; 2002 Jun; 17(3):281-9. PubMed ID: 12136520
[TBL] [Abstract][Full Text] [Related]
55. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers.
Kitamura S; Kondo S; Shinomura Y; Kanayama S; Miyazaki Y; Kiyohara T; Hiraoka S; Matsuzawa Y
Br J Cancer; 2000 Sep; 83(5):668-73. PubMed ID: 10944610
[TBL] [Abstract][Full Text] [Related]
56. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
Elez R; Piiper A; Kronenberger B; Kock M; Brendel M; Hermann E; Pliquett U; Neumann E; Zeuzem S
Oncogene; 2003 Jan; 22(1):69-80. PubMed ID: 12527909
[TBL] [Abstract][Full Text] [Related]
57. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA
Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841
[TBL] [Abstract][Full Text] [Related]
58. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
59. Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine.
Xu Z; Friess H; Solioz M; Aebi S; Korc M; Kleeff J; Büchler MW
Int J Cancer; 2001 Oct; 94(2):268-74. PubMed ID: 11668508
[TBL] [Abstract][Full Text] [Related]
60. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
Herbst RS; Frankel SR
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
